Predicting Plasma Concentration of Risperidone Associated With Dosage Change
Authors:
- Hiroyuki UchidaHUHiroyuki Uchida
- David C. MamoDMDavid C. Mamo
- Bruce G. PollockBPBruce G. Pollock
- Takefumi SuzukiTSTakefumi Suzuki
- Kenichi TsunodaKTKenichi Tsunoda
- Koichiro WatanabeKWKoichiro Watanabe
- Masaru MimuraMMMasaru Mimura
- Robert R. BiesRBRobert R. Bies
- 1 April 2012
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 34 (2) , 182-187
Abstract
Due to high interindividual variability in peripheral pharmacokinetic parameters, dosing of antipsychotics relies on clinical trial and error. This blind process of upward or downward clinical dose titration carries a risk of relapse and adverse effects in the treatment of schizophrenia. Using population pharmacokinetic methods, the authors therefore sought to predict plasma concentrations of risperidone (RIS) plus 9-hydroxyrisperidone (9-OH-RIS) before a dosage change. Two plasma samples were collected at 2 separate given time points for the measurement of RIS and 9-OH-RIS concentrations from 50 patients with schizophrenia or schizoaffective disorder maintained on risperidone (mean ± SD age = 56 ± 15 years; 39 men). After an oral risperidone dose adjustment, a third sample was collected. The plasma concentration of the third sample was individually predicted in a blinded fashion with the 2 baseline plasma concentrations before dose adjustment and clinical and demographic information, using the mixed-effects model with NONMEM that was derived from the data of the Clinical Antipsychotic Trials in Intervention Effectiveness study. The mean (95% confidence interval) prediction errors (in ng/mL) were as low as 0.0 (-1.3 to 1.4) for RIS and 1.0 (-1.1 to 3.0) for 9-OH-RIS. The observed and predicted concentrations of RIS and 9-OH-RIS were highly correlated (r = 0.96, P < 0.0001 and r = 0.92, P < 0.0001, respectively). Antipsychotic plasma concentrations can be predicted before risperidone dose adjustment. In light of the known relationship between plasma drug concentration, dopamine D2 receptor occupancy, and clinical effects, our results confirm that individualized dosing with the measurement of antipsychotic plasma concentrations has the potential for bedside clinical application.Keywords
This publication has 25 references indexed in Scilit:
- Dopamine D2 Receptor Occupancy and Clinical EffectsJournal of Clinical Psychopharmacology, 2011
- Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic DrugsJournal of Clinical Psychopharmacology, 2011
- Clozapine Exposure and the Impact of Smoking and Gender: A Population Pharmacokinetic StudyTherapeutic Drug Monitoring, 2009
- Sex, Race, and Smoking Impact Olanzapine ExposureThe Journal of Clinical Pharmacology, 2008
- A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable RisperidoneAmerican Journal of Psychiatry, 2006
- Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine ConcentrationsJournal of Clinical Psychopharmacology, 2004
- Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studiesStatistics in Medicine, 2004
- Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode SchizophreniaAmerican Journal of Psychiatry, 2000
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Estimation of population characteristics of pharmacokinetic parameters from routine clinical dataJournal of Pharmacokinetics and Biopharmaceutics, 1977